Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
38
ICCM Quote, Financials, Valuation and Earnings
Last price:
$0.67
Seasonality move
:
25.42%
Day range:
$0.65 - $0.68
52-week range:
$0.59 - $1.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.65x
P/B ratio:
5.00x
Volume:
274.6K
Avg. volume:
397.4K
1-year change:
-41.31%
Market cap:
$46.5M
Revenue:
$3.3M
EPS (TTM):
-$0.26
Analysts' Opinion
-
Consensus RatingIceCure Medical Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.13, IceCure Medical Ltd. has an estimated upside of 363.03% from its current price of $0.67.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $0.67.
Fair Value
-
According to the consensus of 1 analyst, IceCure Medical Ltd. has 363.03% upside to fair value with a price target of $3.13 per share.
ICCM vs. S&P 500
-
Over the past 5 trading days, IceCure Medical Ltd. has overperformed the S&P 500 by 1.51% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
IceCure Medical Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IceCure Medical Ltd. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter IceCure Medical Ltd. reported revenues of $850K.
Earnings Growth
-
IceCure Medical Ltd. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter IceCure Medical Ltd. reported earnings per share of -$0.06.
Enterprise value:
36.8M
EV / Invested capital:
--
Price / LTM sales:
13.65x
EV / EBIT:
--
EV / Revenue:
12.38x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.58x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1M
Return On Assets:
-118.3%
Net Income Margin (TTM):
-513.95%
Return On Equity:
-217.45%
Return On Invested Capital:
-195.32%
Operating Margin:
-451.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.9M | $3.7M | $3M | $662K | $850K | |
| Gross Profit | $731K | $1.6M | $1M | $235K | $277K | |
| Operating Income | -$16.1M | -$14.6M | -$15.4M | -$4.3M | -$3.8M | |
| EBITDA | -$15.8M | -$14.3M | -$15.1M | -$4.2M | -$3.8M | |
| Diluted EPS | -$0.26 | -$0.29 | -$0.26 | -$0.08 | -$0.06 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $18M | $17.2M | $13.3M | $13.7M | |
| Total Assets | -- | $20.1M | $19.4M | $15.3M | $15.1M | |
| Current Liabilities | -- | $4.3M | $4.3M | $5M | $5.7M | |
| Total Liabilities | -- | $4.8M | $4.6M | $5.2M | $5.8M | |
| Total Equity | -- | $15.3M | $14.8M | $10.1M | $9.3M | |
| Total Debt | -- | -- | $379K | $222K | $24K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$14.4M | -$10.9M | -$14.2M | -$3.2M | -$3.1M | |
| Cash From Investing | -$7.7M | $9.2M | -$5.3M | $800.4K | -$5.2M | |
| Cash From Financing | $13.6M | $8.1M | $13.8M | $3.4M | $8M | |
| Free Cash Flow | -$14.9M | -$11M | -$14.3M | -$3.2M | -$3.1M | |
ICCM
Sector
Market Cap
$46.5M
$27.9M
Price % of 52-Week High
40.66%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-19.65%
-1.49%
1-Year Price Total Return
-41.31%
-16.66%
Beta (5-Year)
0.997
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.67
200-day SMA
Sell
Level
$0.98
Bollinger Bands (100)
Sell
Level
0.7 - 1
Chaikin Money Flow
Sell
Level
-28M
20-day SMA
Sell
Level
$0.69
Relative Strength Index (RSI14)
Sell
Level
45.47
ADX Line
Sell
Level
13.58
Williams %R
Neutral
Level
-47.8226
50-day SMA
Sell
Level
$0.73
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Sell
Level
-17.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.3832)
Sell
CA Score
(Annual)
Level (-4.5347)
Buy
Beneish M-Score
(Annual)
Level (-2.4429)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (8.9075)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.
Stock Forecast FAQ
In the current month, ICCM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ICCM average analyst price target in the past 3 months is $3.13.
-
Where Will IceCure Medical Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that IceCure Medical Ltd. share price will rise to $3.13 per share over the next 12 months.
-
What Do Analysts Say About IceCure Medical Ltd.?
Analysts are divided on their view about IceCure Medical Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IceCure Medical Ltd. is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is IceCure Medical Ltd.'s Price Target?
The price target for IceCure Medical Ltd. over the next 1-year time period is forecast to be $3.13 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ICCM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IceCure Medical Ltd. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ICCM?
You can purchase shares of IceCure Medical Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IceCure Medical Ltd. shares.
-
What Is The IceCure Medical Ltd. Share Price Today?
IceCure Medical Ltd. was last trading at $0.67 per share. This represents the most recent stock quote for IceCure Medical Ltd.. Yesterday, IceCure Medical Ltd. closed at $0.67 per share.
-
How To Buy IceCure Medical Ltd. Stock Online?
In order to purchase IceCure Medical Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ICCM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ICCM
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
5.00x
1.81x
Price / LTM sales
13.65x
1.58x
Growth Metrics
ICCM
Sector
Revenue growth
28.4%
4.62%
Earnings growth
26.92%
10.5%
Revenue (5-year growth)
15.36%
6.5%
Earnings forecast
-$0.04
-$0.21
Profitability
ICCM
Sector
Profitability FY 2024
$1.3M
$3.6M
Return on invested capital
-195.32%
-31.87%
Return on assets
-118.3%
-28.18%
Return on equity
-217.45%
-37.63%
Earnings Date
Last Earnings Date
Nov
19
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
18
Balance Sheet
ICCM
Sector
Total cash
$10M
$26.4M
Short term investments
--
$25.7M
Total assets
$12.6M
$76.9M
Long term debt
$24K
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
